Oncolytics Biotech
ONCY
20 hedge funds and large institutions have $981K invested in Oncolytics Biotech in 2019 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 4 closing their positions.
173% more capital invested
Capital invested by funds: $360K → $981K (+$621K)
1.8% more ownership
Funds ownership: 1.03% → 2.84% (+1.8%)
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
9% less funds holding
Funds holding: 22 → 20 (-2)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Verition Fund Management
Greenwich,
Connecticut
|
+$742K |
| 2 |
MFG
Magnus Financial Group
New York
|
+$18.1K |
| 3 |
Morgan Stanley
New York
|
+$15.4K |
| 4 |
SC
Scotia Capital
Toronto,
Ontario, Canada
|
+$6.04K |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$1.44K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$54K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$19K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$7.1K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$6.8K |
| 5 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
-$2K |
ONCY Hedge Fund Activity: Q2 2019 in Review
20 of the 4,605 institutional investors tracked by Wall St. Rank reported a position in Oncolytics Biotech (ONCY) for Q2 2019, worth a combined $981K — up 173% from $360K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of ONCY and 3 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 4 added.
The largest buyer was Verition Fund Management, opening a new position worth an estimated $742K. The largest seller was Citadel Advisors, exiting entirely with an estimated $54K sold.
- 20 institutional investors held Oncolytics Biotech (ONCY) as of Q2 2019, down from 22 in Q1 2019.
- Funds reported $981K of Oncolytics Biotech stock for Q2 2019, up 173% quarter-over-quarter.
- 3 funds opened new Oncolytics Biotech positions in Q2 2019 and 4 closed out, a net change of -1 holder.
- The largest Oncolytics Biotech buyer in Q2 2019 was Verition Fund Management, an estimated $742K added.
- The largest Oncolytics Biotech seller in Q2 2019 was Citadel Advisors, an estimated $54K sold.
Based on aggregated 13F filings for Q2 2019.